Abstract
BackgroundAB248 is a fusion of an affinity-attenuated IL-2 mutein and an antibody targeting CD8+ T cells designed to overcome the limitations of wild-type IL-2 and second-generation IL-2Rβγ agonists, “not-α” IL-2...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have